US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

First Trust SMID Growth Strength ETF

31.44

+0.11330.36%

Volume:250.00

Turnover:7.85K

Market Cap:31.44M

PE:- -

High:31.44

Open:31.38

Low:31.38

Close:31.33

52wk High:32.96

52wk Low:24.39

Shares:1.00M

Float Shares:1.00M

Volume Ratio:0.17

T/O Rate:0.02%

Dividend:0.39

Dividend Rate:1.25%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan

MT Newswires Live

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

Dimerix's Market Value Falls Despite Full Funding, Record Licensing Deal, Euroz Says

MT Newswires Live

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari

Benzinga_recent_news

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis

Press Release: Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Dimerix Enters License Agreement to Commercialize DMX-200 Drug Candidate in the US, Shares Surge 43%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/FSGS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FSGS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","market":"US","secType":"STK","nameCN":"First Trust SMID Growth Strength ETF","latestPrice":31.44,"timestamp":1761595200000,"preClose":31.3267,"halted":0,"volume":250,"delay":0,"floatShares":1000002,"shares":1000002,"eps":0,"marketStatus":"Pre-Mkt","change":0.1133,"latestTime":"10-28 05:58:59 EDT","open":31.38,"high":31.44,"low":31.38,"amount":7851.3565,"amplitude":0.001915,"askPrice":49.98,"askSize":100,"bidPrice":12.64,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1761658200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":31.44,"sharesOutstanding":1000002,"nav":31.34,"aum":31340062.68,"dividendRate":0.0125,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.38,"preClose":31.44,"latestTime":"16:04 EDT","volume":3,"amount":94.32,"timestamp":1761595453502},"volumeRatio":0.16540953763965155},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","floatShares":1000002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.16540953763965155,"shares":1000002,"dividePrice":0.393,"high":31.44,"amplitude":0.001915,"preClose":31.3267,"low":31.38,"week52Low":24.39,"pbRate":"--","week52High":32.96,"institutionHeld":0,"latestPrice":31.44,"eps":0,"divideRate":0.0125,"volume":250,"delay":0,"ttmEps":0,"open":31.38,"prevYearClose":29.7151,"prevWeekClose":31.3267,"prevMonthClose":31.221,"prevQuarterClose":31.221,"fiveDayClose":31.065,"twentyDayClose":31.275,"sixtyDayClose":30.4191},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FSGS\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FSGS","amount":0.3931,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"FIRST TRUST EXCHANGE-TRADED FUND VI FIRST TRUST SMID GROWTH STRENGTH ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FSGS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":0.3931,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FSGS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FSGS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577616183","title":"Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2577616183","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577616183?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:00","pubTimestamp":1761134400,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Oct.  22, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3171023/0/en/Vera-Therapeutics-to-Host-an-Investor-Call-and-Webcast-to-Provide-an-ORIGIN-3-Update-on-November-6-2025-at-4-30-pm-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRX11.SGD","BK4585","LU1244550221.USD","BK4181","IE00BFSS7M15.SGD","BK4550","IE0004445015.USD","LU0726765562.USD","BK4209","LU1430594728.SGD","MCD","LU1718418525.SGD","VERA","LU2347655073.USD","LU1732799900.SGD","FSGS","LU1732800096.USD","BK4534","BK4581","LU0942090050.USD","LU0417517546.SGD","BK4561","ET","IE00BJTD4N35.SGD","LU0795875086.SGD","LU0868494708.USD","BK4144","BK4218","LU1035773651.USD","LU1244550494.USD","IE00BFSS8Q28.SGD","TACI","LU1069347547.HKD","BK4539","IE00BJJMRY28.SGD","HST","LU0912757837.SGD","LU1585245621.USD","LU0795875169.SGD","LU0868494617.USD","LU2347655156.SGD","IE00B7KXQ091.USD","BK4610","LU2279689827.SGD","LU0256863811.USD","IE00BJTD4V19.USD","BK4566","LU2133065610.SGD","LU1074936037.SGD","BK4588"],"gpt_icon":0},{"id":"2576272059","title":"Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576272059","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576272059?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:12","pubTimestamp":1760706720,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168657/0/en/Vera-Therapeutics-Announces-ORIGIN-3-Late-Breaking-Abstract-Selected-as-Featured-Oral-Presentation-at-Opening-Plenary-Session-of-ASN-Kidney-Week-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","BK4585","BK4550","LU1035773651.USD","LU0868494617.USD","BK4539","LU0795875169.SGD","BK4534","LU2347655073.USD","LU1244550577.SGD","MCD","LU1074936037.SGD","BK4581","LU1244550494.USD","LU0795875086.SGD","LU2347655156.SGD","BK4139","IE00BFSS8Q28.SGD","IE00BJTD4V19.USD","LU0256863811.USD","FSGS","LU0912757837.SGD","BK4588","BK4566","LU0868494708.USD","IE00B7KXQ091.USD","LU1585245621.USD","IE00BJJMRX11.SGD","LU0417517546.SGD","LU1732799900.SGD","VERA","IE00BFSS7M15.SGD","BK4504","LU2279689827.SGD","LU0942090050.USD","IE00BJJMRY28.SGD","LU1244550221.USD","BK4610","BK4209","IE0004445015.USD","LU1069347547.HKD","LU1430594728.SGD","LU0726765562.USD","LU1732800096.USD","TACI","LU2133065610.SGD","IE00BJTD4N35.SGD"],"gpt_icon":0},{"id":"2571336480","title":"Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2571336480","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571336480?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:49","pubTimestamp":1759189755,"startTime":"0","endTime":"0","summary":"Dimerix  said its drug candidate, DMX-200, for the treatment of focal segmental glomerulosclerosis , a serious and rare disease that attacks the kidney, has received Orphan Drug designation in Japan, according to a Tuesday filing with the Australian bourse.Japanese partner FUSO Pharmaceutical Industries has exclusive rights to develop, register, and commercialize DMX-200 to treat FSGS in the Japanese market.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","FSGS","BK7501","DXB.AU"],"gpt_icon":0},{"id":"2564393460","title":"ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression","url":"https://stock-news.laohu8.com/highlight/detail?id=2564393460","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564393460?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:55","pubTimestamp":1756900500,"startTime":"0","endTime":"0","summary":"ZyVersa is developing Cholesterol Efflux MediatorVAR 200 to mediate removal of damaging excess cholesterol and other lipids from the kidneys’ filtration system. VAR 200 directly removes lipids from ki","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/03/3143489/0/en/ZyVersa-Therapeutics-Highlights-Lipidomic-Data-in-Alport-Syndrome-and-DKD-Reinforcing-the-Need-for-Drugs-to-Attenuate-Damaging-Renal-Lipid-Accumulation-to-Mitigate-Disease-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4139","FSGS","ZVSA","BK4007"],"gpt_icon":0},{"id":"2564893114","title":"Dimerix's Market Value Falls Despite Full Funding, Record Licensing Deal, Euroz Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2564893114","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564893114?lang=en_us&edition=fundamental","pubTime":"2025-09-01 13:13","pubTimestamp":1756703593,"startTime":"0","endTime":"0","summary":"Dimerix  remained fully funded and in its strongest position to date, yet its market value has fallen by AU$18 million since its record AU$940 million US licensing agreement, Euroz Hartleys said in a report on Monday.Despite receiving AU$48 million in upfront cash and securing up to AU$1.4 billion in potential licensing value across four agreements, the company's shares remain unchanged at around AU$0.45, the same level as a year ago, the broker noted, Euroz said.The company holds enough cash to complete its Phase 3 clinical trial for focal segmental glomerulosclerosis , a rare kidney disease, and could receive up to AU$119 million in development milestone payments and AU$56 million on first US sales within 18 months, along with additional milestone payments from other regions, Euroz added.While the clinical trial risks are still present, the regulatory environment in the US has likely improved, the firm observed.The firm maintained Dimerix's speculative buy rating and its AU$1.68 pric","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7501","FSGS","DXB.AU","BK7067"],"gpt_icon":0},{"id":"2563057684","title":"FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari","url":"https://stock-news.laohu8.com/highlight/detail?id=2563057684","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563057684?lang=en_us&edition=fundamental","pubTime":"2025-08-29 00:40","pubTimestamp":1756399200,"startTime":"0","endTime":"0","summary":"FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/28/Doctor-Utilizing-Advanced-Digital-Tablet.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/28/Doctor-Utilizing-Advanced-Digital-Tablet.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/08/47393162/fda-eases-monitoring-burden-for-kidney-disease-patients-on-travere-therapeutics-filspari","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/08/47393162/fda-eases-monitoring-burden-for-kidney-disease-patients-on-travere-therapeutics-filspari","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","EFT","BK4539","BK4007","FSGS","LENZ"],"gpt_icon":0},{"id":"2559462489","title":"Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2559462489","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559462489?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:01","pubTimestamp":1755028860,"startTime":"0","endTime":"0","summary":"MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively Enrol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/12/3132101/0/en/Maze-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","MAZE","BK4007"],"gpt_icon":0},{"id":"2555833451","title":"Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2555833451","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555833451?lang=en_us&edition=fundamental","pubTime":"2025-07-31 19:05","pubTimestamp":1753959900,"startTime":"0","endTime":"0","summary":"Received U.S. FDA approval for EMPAVELI (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnouncedcapped royalty purchase agreement with Sobi under which Apelli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/31/3124861/0/en/Apellis-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989764664.SGD","LU1951200564.SGD","BK4612","LU0823421333.USD","LU1303367103.USD","LU2098885051.SGD","LU1316542783.SGD","LU2054465674.USD","IE00BMPRXR70.SGD","LU1951198990.SGD","FSGS","LU0198837287.USD","IE0009356076.USD","LU0127658192.USD","BK4614","LU2360106780.USD","BK4554","BK4532","LU0109392836.USD","LU2458330243.SGD","BK4512","LU1880398554.USD","IE00BMPRXN33.USD","LU1880398471.USD","LU0823434740.USD","LU0081259029.USD","BK4087","LU1923623000.USD","IE00B5949003.HKD","IE0004445239.USD","LU0082616367.USD","LU2264538146.SGD","LU0642271901.SGD","BK4585","LU0889565833.HKD","LU1988902786.USD","LU0056508442.USD","CHMP","LU1852331112.SGD","LU2458330169.SGD","LU2250418816.HKD","BK4605","BK4573","BK4529","LU1803068979.SGD","BK4081","EMA","LU1064131342.USD","LU0390134368.USD"],"gpt_icon":1},{"id":"2549544383","title":"ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2549544383","media":"GlobeNewswire","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549544383?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:52","pubTimestamp":1751975520,"startTime":"0","endTime":"0","summary":"ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3111633/0/en/ZyVersa-Therapeutics-Supports-FDA-Authorized-Emergency-Compassionate-Use-of-Cholesterol-Efflux-Mediator-VAR-200-in-a-Patient-with-ApoCII-Amyloidosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","LENZ","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2535138002","title":"Press Release: Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2535138002","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535138002?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:01","pubTimestamp":1747252860,"startTime":"0","endTime":"0","summary":"MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026. MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025. Strong Balance Sheet with $294.4 Million in Cash and Cash Equivalents, Expected to Provide Cash Runway into H2 2027. SOUTH SAN FRANCISCO, Calif., May 14, 2025  -- Maze Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today reported financial results for the first quarter ended March 31, 2025, and reiterated upcoming milestones.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007","FSGS"],"gpt_icon":0},{"id":"2533803576","title":"Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2533803576","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533803576?lang=en_us&edition=fundamental","pubTime":"2025-05-06 20:00","pubTimestamp":1746532800,"startTime":"0","endTime":"0","summary":"-- On track to announce the primary endpoint results from the atacicept. pivotal Phase 3 ORIGIN trial in IgA Nephropathy  in 2Q 2025;planning for Biologics License Application  submission for atacicept. -- Expanded atacicept development program across multiple autoimmune kidney. \"We are rapidly approaching a significant Vera milestone with the upcoming primary endpoint results from the pivotal atacicept ORIGIN 3 trial, and if successful, we expect this to enable a BLA submission to the FDA in the second half of this year, which may allow approval and commercial launch in 2026. If approved, we believe that atacicept has the potential to advance the standard of care in IgA nephropathy,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"The Vera team is well-positioned to build on the success of the lead atacicept development program in IgAN, with the expansion into additional potential indications in other autoimmune kidney diseases and beyond.\". -- Plan to submit a Bio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732799900.SGD","LU1244550221.USD","LU1718418525.SGD","LU1732800096.USD","LENZ","LU0942090050.USD","BK4534","BK4007","FSGS","LU1244550494.USD","IE0004445015.USD","LU1244550577.SGD","BK4585","LU0795875086.SGD","LU2279689827.SGD","TACI","BK4550","LU2133065610.SGD","BK4139","LU0912757837.SGD","BK4588","LU1430594728.SGD","PMN","IE00BFSS7M15.SGD","IE00BJTD4N35.SGD","BK4539","LU0256863811.USD","BK4581","IE00BFSS8Q28.SGD","IE00BJTD4V19.USD","VERA","BKV","LU0868494617.USD","BK4610","BK4213","LU0868494708.USD","IE00B7KXQ091.USD","LU0417517546.SGD","LU0795875169.SGD","IE00BJJMRX11.SGD","BK4209","BK4566","IE00BJJMRY28.SGD","LU2347655156.SGD","BK4504","LU1585245621.USD"],"gpt_icon":1},{"id":"2532014900","title":"Dimerix Enters License Agreement to Commercialize DMX-200 Drug Candidate in the US, Shares Surge 43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532014900","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532014900?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:02","pubTimestamp":1746061329,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) and Amicus Therapeutics entered into an exclusive license agreement for the commercialization of Dimerix's drug candidate DMX-200 in the US, according to a Thursday Australian bourse","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FSGS","BK7501","DXB.AU","BK7508","BK7067","DMX"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}